Why Pediatric CAR-T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe.

Hanquet L, Dogné JM, Musuamba FT.

Open source

DOI
10.1002/cpt.70299
Published
2026-05-08
Container
Clin Pharmacol Ther
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cpt.70299,
  title = {Why Pediatric CAR-T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe.},
  author = {Hanquet L and  Dogné JM and  Musuamba FT.},
  year = {2026},
  journal = {Clin Pharmacol Ther},
  doi = {10.1002/cpt.70299},
  url = {https://doi.org/10.1002/cpt.70299}
}

RIS

TY  - JOUR
TI  - Why Pediatric CAR-T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe.
AU  - Hanquet L
AU  -  Dogné JM
AU  -  Musuamba FT.
PY  - 2026
JO  - Clin Pharmacol Ther
DO  - 10.1002/cpt.70299
UR  - https://doi.org/10.1002/cpt.70299
ER  - 

APA

L, H., JM, D., & FT., M. (2026). Why Pediatric CAR-T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe.. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.70299

Source records